Mucolytic Effectiveness of Tacholiquine ® in Chronic Bronchitis
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the mucolytic activity of Tacholiquine® compared to
saline (0.9%) in chronic bronchitis patients. Lung function parameters, biomarker profiles in
sputum and serum, and clinical symptoms by standardized questionnaires [COPD activity index
(CAT), Baseline Dyspnea Index (BDI) & Transition Dyspnea Index (TDI)and the St. George's
Respiratory Questionnaire (SGRQ)] will be evaluated in response to Tacholiquine® vs. saline
in chronic bronchitis patients.